BIOLASE (BIOL) Market Value

BIOLASE, Inc. is expanding its presence in the US market by developing wholesale supplies of laser systems for dental operations. This growth trend is based on the willingness of private practices to upgrade legacy instrumentation and the qualification level of physicians. Serving as an assessment tool, this price chart recorded a value of 0.00, underscoring the brand's status as a benchmark for reliability and premium quality within its niche.

BIOL BIOLASE: Market Value in the range 07/04/2022 - 08/04/2024

Financial and market metric breakdowns for Biolase Inc. (BIOL)

- current price and projected stock value:

Stock Price BIOLASE|BIOL - Analyst Median Target

- market capitalization details:

Market Value Biolase Inc.|BIOL - Total Enterprise Value

- book value of equity indicators:

Net Assets per Single Share BIOLASE|BIOL - Company Book Value|Market Value to Book Value Ratio biolase.com|BIOL - Company Total Asset Base

- debt and liquidity data:

- business earnings and investment ratios data:

BIOL - Net Profit|Expected Profit BIOLASE, Inc.|BIOL - Price to Earnings Ratio|Forward P/E Multiple Biolase, Inc.|BIOL - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Biolase Inc.|BIOL - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) BIOLASE|BIOL - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth biolase.com|BIOL - Earnings per share growth this year|Expected earnings per share growth for next year BIOLASE, Inc.

Initial company analysis:BIOLASE BIOL

The market capitalization of BIOLASE, Inc. (BIOL) reflects the aggregate value of all shares of the dental laser manufacturer. This metric measures the market perception of the business, where the asset price is shaped by the emotional fluctuations of investors. By analyzing the company's current market capitalization, one can identify the risks of overpayment during periods of euphoria. The trend of this indicator correlates directly with the pace of clinic digitalization. Stable liquidity mitigates the impact of long sales cycles on the overall valuation.

Competitors of BIOLASE, Inc. (BIOL)